These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 8602374)

  • 1. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
    Oberg KC; Bauman JL
    Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature.
    Tschida SJ; Guay DR; Straka RJ; Hoey LL; Johanning R; Vance-Bryan K
    Pharmacotherapy; 1996; 16(4):663-74. PubMed ID: 8840374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythromycin-induced torsades de pointes and ventricular fibrillation in a patient with Legionella pneumonia.
    de Koning J; van der Hoeven H; Hamer B; Thompson J
    Neth J Med; 1994 Apr; 44(4):131-5. PubMed ID: 8196823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Torsades de pointes associated with acquired long QT syndrome: observation of 7 cases.
    Takahashi N; Ito M; Inoue T; Koumatsu K; Takeshita Y; Tsumabuki S; Tamura M; Inoue K; Maeda T; Saikawa T
    J Cardiol; 1993; 23(1):99-106. PubMed ID: 8164140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.
    Tisdale JE; Kovacs R; Mi D; McCabe GP; Cariera BL; Sharma N; Rosman H
    Pharmacotherapy; 2007 Feb; 27(2):175-82. PubMed ID: 17253907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
    Tisdale JE; Rasty S; Padhi ID; Sharma ND; Rosman H
    J Clin Pharmacol; 2001 Dec; 41(12):1310-8. PubMed ID: 11762558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC; Quasny HA
    Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
    Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
    Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes.
    Isbister GK; Balit CR; Macleod D; Duffull SB
    J Clin Psychopharmacol; 2010 Aug; 30(4):391-5. PubMed ID: 20531221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
    Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
    J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Erythrocyte-induced "torsade de pointes" ventricular tachycardia].
    Lengyel C; Várkonyi T; Fazekas T
    Orv Hetil; 1997 Apr; 138(16):1003-6. PubMed ID: 9153994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythromycin induced Torsades de Pointes: case report and review of the literature.
    Rezkalla MA; Pochop C
    S D J Med; 1994 May; 47(5):161-4. PubMed ID: 8047870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythromycin induced torsades de pointes.
    Wong CB; Windle J
    Nebr Med J; 1995 Sep; 80(9):285-6. PubMed ID: 7566254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case series of drug-induced long QT syndrome and Torsade de Pointes.
    Tong KL; Lau YS; Teo WS
    Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of ventricular fibrillation triggered by pause-dependent torsades de pointes associated with acquired long QT interval: role of QT dispersion and left ventricular function.
    Da Costa A; Chalvidan T; Belounas A; Messier M; Viallet M; Mansour H; Lamaison D; Djiane P; Isaaz K
    J Cardiovasc Electrophysiol; 2000 Sep; 11(9):990-7. PubMed ID: 11021469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxifloxacin and torsade de pointes.
    Dale KM; Lertsburapa K; Kluger J; White CM
    Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.